

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

.....

Current Directions in Autoimmunity

Vol. 2

Series Editor

A. N. Theofilopoulos, La Jolla, Calif.

KARGER

Basel · Freiburg · Paris · London · New York ·
New Delhi · Bangkok · Singapore · Tokyo · Sydney

.....

Biologic and Gene Therapy of Autoimmune Disease

Volume Editor

C. G. Faithman, Stanford, Calif.

18 figures, 1 in color and 11 tables, 2000

KARGER

Basel · Freiburg · Paris · London · New York ·
New Delhi · Bangkok · Singapore · Tokyo · Sydney

RC600
B56
2000

Current Directions in Autoimmunity

.....

C.G. Fathman

Professor, Director, Center for Clinical Immunology at Stanford (CCIS),
Stanford University School of Medicine, Division of Immunology/Rheumatology,
Rm 5021, Stanford CA 94305-5111 (USA)

Library of Congress Cataloging-in-Publication Data
LC number 99-088881

Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 2000 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel
ISSN 1422-2132
ISBN 3-8035-0949-1

Contents

.....

- 1 **Oral Tolerance as a Treatment Modality for Autoimmune Diseases**
Whitacre C.C.; Campbell K.A. (Columbus, Ohio)
- 24 **Anti-CD4 Monoclonal Antibody Therapy in Human Autoimmune Diseases**
Schulze-Koops H. (Erlangen); Lipsky P.E. (Dallas, Tex.)
- 50 **Novel Concepts of Tumor Necrosis Factor Action in Autoimmune Pathology**
Rimmington D.S. (Sydney); Sedgwick J.D. (Palo Alto, Calif.)
- 83 **Anti-TNF α Therapy in Rheumatoid Arthritis - Current and Future Directions**
Taylor P.C.; Williams R.O.; Maini R.N. (London)
- 103 **Cytokine-Directed Targeting in Chronic Arthritis**
van den Berg W.B.; Joosten L.A.B.; Lubberts E. (Nijmegen)
- 126 **Interleukin-10: Therapeutic Prospects in Rheumatoid Arthritis**
St. Clair E.W. (Durham, N.C.)
- 150 **Immunomodulation of Crohn's Disease**
van Deventer S.J.H. (Amsterdam)
- 167 **Retroviral and Lentiviral Gene Therapy for Autoimmune Disease**
Smith R.; Nolan G.P. (Stanford, Calif.)
- 189 **Application of Gene Therapy in Autoimmune Disease**
Fathman C.G.; Seroogy C.M. (Palo Alto, Calif.)
- 203 **DNA Vaccination in the Treatment of Autoimmune Disease**
Carren H.; Steinman L. (Stanford, Calif.)
- 217 **Author Index**
- 218 **Subject Index**

Interleukin-10: Therapeutic Prospects in Rheumatoid Arthritis

E. William St. Clair

Duke South Hospital, Duke University Medical Center, Durham, N.C., USA

Introduction

The hallmark of interleukin-10 (IL-10) is its capacity to inhibit cytokine synthesis and downregulate a cellular immune response. Originally identified as a T helper 2 (Th2) cytokine [1], IL-10 has been increasingly recognized to play a much broader role in the regulation of immune function. IL-10 is a pleiotropic cytokine with diverse effects on a variety of cell types [reviewed in 2, 3]. It suppresses Th1-dependent cellular immune responses and supports Th2-dependent antibody-mediated immune responses. IL-10 inhibits the capacity of macrophages to synthesize proinflammatory cytokines and other mediators and serves as part of an endogenous feedback loop to restrain inflammatory stimuli.

Cytokine networks are pivotal in the pathogenesis of rheumatoid arthritis (RA). IL-10 is expressed by macrophages and T cells in the rheumatoid synovium [4]. While inhibitory, the levels of IL-10 are presumably inadequate to control joint inflammation. The inflammatory response is launched into overdrive by proinflammatory cytokines such as tumor necrosis factor (TNF)- α and IL-1 [5]. The vital role played by these proinflammatory cytokines in joint inflammation has been confirmed in clinical trials which show that TNF- α blockade and, to a lesser extent, IL-1 antagonism reduce the signs and symptoms of RA [6-11]. The administration of IL-10 has a similar therapeutic potential through its ability to suppress the production of proinflammatory cytokines.

Studies in both humans and mice provide insights into IL-10 functions. IL-10 shows relative species specificity. Human IL-10 has 71% sequence homology with mouse IL-10 [12, 13] and acts on both human and murine cells

[3]. Mouse IL-10 demonstrates no activity on human cells [3]. Part of the human IL-10 sequence is highly homologous with an open-reading frame (BCRF1) in the Epstein-Barr virus (EBV) genome [13]. The viral IL-10 (vIL-10) shares with human and mouse IL-10 many of the same biological functions.

This chapter reviews the biology of IL-10 in the context of its possible therapeutic use in RA. Awareness of the diverse effects of IL-10 is crucial to properly design and interpret clinical studies. Also, individual differences in the genetic regulation of IL-10 may ultimately predict which patients may respond clinically to IL-10 interventions. Current clinical investigations of IL-10 may not only expand our therapeutic armamentarium for RA, but also shed new light on the complex mechanisms regulating aberrant immune responses.

Regulation of IL-10 Production

IL-10 is tightly regulated at the cellular level. Both murine and human monocytes produce high levels of IL-10 upon activation with the bacterial endotoxin lipopolysaccharide (LPS). LPS initially triggers a burst of TNF- α , IL-1, IL-6, and GM-CSF that reaches a peak at 3.5-7.5 h followed 20-48 h later by maximal synthesis of IL-10 [14]. LPS-stimulated IL-10 production depends on the synthesis of TNF- α and IL-1 [15, 16] as well as cognate interactions between monocytes and T cells [16]. TNF- α and IL-1 alone may also stimulate monocyte IL-10 production. The synthesis of IL-10 mRNA is inhibited by endogenous IL-10 production, creating an autoregulatory feedback loop [14].

Other factors regulate monocyte IL-10 production. TGF- β , IFN- α , and IFN- β enhance LPS-stimulated release of IL-10 [17-19]. IL-10 secretion may also be stimulated by ligating CD23, the low affinity IgE receptor [20]. IL-10 and IL-12 often are regulated in a reciprocal fashion. Ligand of the macrophage Fc γ receptor 1 (Fc γ RI) upregulates IL-10 production and inhibits IL-12 synthesis [21]. Histamine also stimulates IL-10 synthesis and suppresses IL-12 production [22]. Both IFN- γ and IL-4 downregulate LPS-induced IL-10 production [23, 24].

T cells produce IL-10, but in levels lower than monocyte/macrophages. The T cell-derived cytokines, including IL-10, can polarize the immune system toward a cellular or humoral response. The nomenclature for Th cell subsets is based on such cytokine patterns and includes the Th0, Th1 and Th2 subsets. In mice, Th1 cells produce IL-2, IFN- γ , and TNF- β , while Th2 cells generate IL-4, IL-5, IL-6 and IL-13 [25]. Th0, a precursor subset, produces IL-2, IFN- γ , IL-4 and IL-10. Murine Th2 and Th0 cells synthesize IL-10 [1, 25]. The

differentiation of the immune response is primarily determined by the relative amounts of IL-12 and IL-4. Monocyte-derived IL-12 differentiates the immune response to a Th1 cytokine pattern and cellular immunity. In comparison, IL-4 drives the immune system response to a Th2 cytokine profile which stimulates B cell-mediated humoral immunity, deactivates monocytes, and induces allergic responses [25]. Initial exposure of naive T cells to IL-4 polarizes the immune response to a Th2 phenotype. After about 3 weeks, previously committed Th1 cells restimulated with IL-4 respond by secreting IL-10, but not IL-4 or IFN- γ [26].

In man, T cell subsets with strictly Th1 and Th2 patterns of cytokine secretion are not readily distinguished by this classification system. Thus, the terminology Th1- and Th2-like cells has been used to describe overlapping phenotypes. Th0, Th1-like, and Th2-like cells have each been shown to produce IL-10. A high ratio of IL-10 to IFN- γ or IL-2 may determine the capacity of Th cells to inactivate an inflammatory response [27].

CD4 T cells secrete IL-10 when stimulated by anti-CD3 [27], anti-T cell receptor, anti-CD2 and anti-CD45 monoclonal antibodies, IL-1, phorbol myristate acetate, and forskolin, an activator of adenylyl cyclase [28]. IL-4 has been shown to enhance IL-10 gene expression in murine Th2 cells without engagement of the T cell receptor [29]. IL-4 inhibits monocyte IL-10 production and stimulates T cell IL-10 secretion and, thereby, exerts paradoxical effects on the inflammatory response. IL-7 induces IL-10 mRNA in T cells [29]. The neuropeptides somatostatin and calcitonin gene-related protein stimulate murine antigen-specific Th0 and Th2 clones to synthesize IL-10 [30]. Other cell types that produce IL-10 include NK cells [31], B cells [32], EBV-transformed B cells [33], B cell lymphomas [34], mast cells [35], and keratinocytes [36].

The production of IL-10 may be potentially influenced by the rate of transcription, mRNA stability, efficiency of translation, and posttranslational events. While the synthesis of IL-10 appears to be controlled primarily at the transcriptional level [37], the 3'-untranslated region of the IL-10 mRNA contains multiple copies of the AU instability element. Thus, IL-10 mRNA is probably unstable in unactivated cells [34]. Individuals differ in the capacity of their peripheral blood cells to produce IL-10 in response to LPS. It has been estimated that 75% of these interindividual differences in LPS-stimulated IL-10 production are determined by heritability [39]. The innate capacity to generate IL-10 may be clinically relevant as suggested by the correlation between high IL-10 production and septic shock in bacteremic patients [40] and fatal outcome from meningococcal infection [39].

The regulation of IL-10 transcription has been investigated by analyzing the 5' flanking sequences of the human IL-10 gene. These studies identify a

TATA box at position -77 [41], several positive and negative regulatory elements [42], two highly polymorphic dinucleotide repeats (microsatellites) located 1.1 and 4.0 kb of the transcription initiation site [43, 44], and three polymorphisms at positions -1082, -819 and -592 [45]. The G to A nucleotide polymorphism at position -1082 is located within a putative binding site for the Ets transcription factors [41, 46]. The C to T nucleotide polymorphism at position -819 lies within a putative positive regulatory region. The C to A nucleotide polymorphism resides within a putative STAT-3 binding site and a negative regulatory region [41, 46]. The 5' flanking sequence of the IL-10 gene also contains binding sites for NF κ B and REL proteins and STAT-1, as well as other cytokine response elements [42]. Preliminary evidence indicates that the IL-10 gene can specifically recognize members of the NF κ B family of transcription factors [47].

The alleles at two microsatellite loci have been used to define haplotypes which are associated with different levels of LPS-induced IL-10 secretion by human blood cells [37]. In one study, individual haplotypes containing the allele IL-10.R2/IL-10.G14 were correlated with the highest IL-10 secretion; those defined by the allele IL-10.R3/IL-10.G7 had the lowest IL-10 secretion [37]. The -1082*A and *G alleles have been associated with low and high IL-10 production *in vitro*, respectively [45]. Furthermore, low levels of IL-10 production *in vitro* have been correlated with the ATA haplotype [46]. These data suggest that genotype may endow an individual with an innate capacity to secrete IL-10. Low IL-10-producing individuals might be at greater risk for RA or severe forms of this disease than high IL-10 producers. However, an analysis of 108 patients with early RA and 128 healthy controls did not reveal a significant correlation between disease and the presence of the -1082*A allele [48]. Similar negative results have been obtained in a study of 44 patients with Felty's syndrome, 117 patients with RA, and 295 healthy controls [49]. Eskdale et al. [50] have found that the IL-10.R2 allele occurs more frequently in controls than in Caucasians and African-Americans with RA. This finding shows paradoxically an association between high IL-10 production and disease likelihood.

Biological Properties of IL-10

IL-10 has diverse effects on many cells (table 1). In monocyte cultures, IL-10 inhibits LPS- or IFN- γ -induced stimulation of TNF- α , IL-1, IL-6, IL-8, GM-CSF and G-CSF [14]. The inhibition of TNF- α and GM-CSF production is over 90% [14]. vIL-10 similarly inhibits LPS-stimulated TNF- α and GM-CSF production [51]. The reduction in cytokine protein correlates

Table 1. Biological properties of IL-10

Inhibitory
Monocyte/macrophage
Inhibits production of TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, GM-CSF and G-CSF production
Inhibits generation of prostaglandins, NO, reactive oxygen species
Reduces expression of MHC class I and II molecules, CD80, CD86, ICAM-1 and formyl peptide receptor
Inhibits production of MIP-1 α and MIP-1 β
Inhibits production of soluble p35 and p75 TNF receptors
Neutrophils
Inhibits production of TNF- α , IL-1, IL-8
Reduces expression of formyl peptide receptor
T cells
Inhibits IL-2 production
Eosinophils
Inhibits TNF- α , GM-CSF and IL-8 production
Stimulatory
Monocyte/macrophage
Upregulates expression of Fc γ I
T cells
Protection from apoptosis
Chemoattractant for CD8 T cells
B cells
Stimulates proliferation, differentiation and Ig production
Increases IgG4 and IgE production
Protects against apoptosis
Mast cells
Stimulates proliferation

on Northern blots with a decrease in the steady-state amounts of the individual mRNAs [14]. The IL-10-induced reduction in LPS-stimulated cytokine mRNAs appears to occur at the posttranscriptional level in mouse [52] and at the transcriptional level in humans [53].

Florentino et al. [1] initially reported that murine IL-10, a product of Th2 cells, inhibited macrophage-dependent IFN- γ production by Th1 cells. Human and vIL-10 also inhibit IFN- γ production by Th cells [54]. This inhibitory effect on T cell cytokine synthesis results from reduced antigen-presenting capacity of monocytes. IL-10 downregulates class II MHC mole-

cules on antigen-presenting cells (APCs) [14, 55] by inhibiting the transport of class II molecules from the cytoplasm to the cell membrane [56]. IL-10 also suppresses the costimulatory properties of monocytes by decreasing the expression of ICAM-1, CD80 and CD86 [57]. Monocyte-derived IL-12 is required early in the induction of Th1 responses. IL-12-driven T cell antigenic stimulation is negatively regulated by IL-10. IL-10 exerts this effect on IL-12 by decreasing the transcription of the p40 subunit of the IL-12 heterodimer without altering its mRNA stability [58].

IL-10 affects other aspects of monocyte activation and function. IL-10 inhibits LPS- and hyaluronan-induced expression of macrophage inflammatory protein (MIP)-1 α and MIP-1 β , two members of the C-C class of chemokines [59, 60]. IL-10 blocks concanavalin A-stimulated activity of prostaglandin H synthase-2/cyclooxygenase-2 and prostaglandin E $_2$ -dependent synthesis of interstitial collagenase and gelatinase B (PGHS-2, COX-2) [61]. IL-10 markedly suppresses macrophage release of reactive oxygen intermediates [62] and nitric oxide (NO) [63]. High levels of NO are catalyzed by the inducible form of nitric oxide synthase (iNOS, NOS2), which is upregulated in circulating monocytes and synovial macrophages from patients with active RA [64]. The inflammatory response is dampened by cytokine inhibitors, such as IL-1 receptor antagonist (IL-1ra) and soluble TNF receptors. IL-10 increases soluble p75 TNF receptor levels in human monocyte cultures and diminishes monocyte cell surface p75 TNF receptors [65]. IL-10 by itself induces human monocytes to secrete low levels of soluble IL-1ra and significantly enhances LPS-stimulated production of IL-1ra [66]. IL-10 also upregulates Fc γ RII/CD64 expression in human monocytes [67], a potentially proinflammatory effect.

IL-10 acts directly on CD4 T cells to inhibit their production of IL-2 [68, 69]. Repetitive stimulation of murine CD4 T cell clones with IL-10 generates a T cell subset with low proliferative capacity and a unique cytokine profile [70]. These T cells, designated Tr1 cells, produce high levels of IL-10, very low levels of IL-2, and no detectable IL-4; the levels of IL-5, IFN- γ and TGF- β are similar to those of Th0 cell clones [70]. The IL-10 production by Tr1 cells probably explains their low proliferative capacity [70]. Tr1 cells suppress antigen-specific T cell responses *in vitro* and the development of inflammatory bowel disease in a SCID mouse model [70]. However, in mice, chronic IL-10 treatment fails to induce T cell tolerance in allogeneic bone marrow recipients [71].

IL-10 also affects the behavior of CD8 T cells depending on their state of activation. Tumor and allospecific CD8 cytotoxic T cells pretreated with IL-10 show a reduction in autologous cytotoxic T lymphocyte-mediated, class I MHC-restricted tumor-specific lysis and allospecific cytotoxicity against EBV-

transformed lymphoblastoid cell lines [72]. This loss of cytotoxicity is associated with a decrease in the cell surface expression of class I MHC molecules, suggesting a novel mechanism of immune tolerance [72]. These effects are mediated through the capacity of IL-10 to inhibit APC costimulatory function [73]. T cells from patients with acute EBV-induced infectious mononucleosis rapidly die in vitro. However, these activated T cells are protected from undergoing apoptosis by treatment with human and vIL-10 [74]. Since IL-10 has similar effects on the survival of IL-2-dependent CD4 T cells [75], this cytokine may function in vivo to regulate T cell survival.

The effect of IL-10 on other cell types may have clinical implications. In cultures of neutrophils, IL-10 inhibits LPS-induced stimulation of TNF- α , IL-1, IL-8 and IL-12 production [76] and the surface expression of formyl peptide receptor [77]. Neutrophil surface expression of FcR γ is not down-regulated by IL-10, unlike the situation for human monocytes [67]. IL-10 may modulate the inflammatory response in asthma and allergic disease by deactivating eosinophils [78]. In addition, IL-10 inhibits macrophage chemotactic protein-1 production by activated gut epithelial cells [79], which may relate to mechanisms of bowel inflammation.

IL-10 stimulates the growth and differentiation of thymocytes, mast cells, and B cells [80-82]. IL-10 regulates humoral immunity and isotype switching. When human B cells are activated by IL-10 and an anti-CD40 monoclonal antibody they proliferate, differentiate into Ig-secreting cells, and switch to IgA, IgG1, and IgE isotypes [83]. IL-10 augments IgG4 production. On the other hand, IL-10 decreases the IL-4-induced switch to IgE, but enhances IgE production by B cells already switched to this isotype [83]. IL-10 prevents the spontaneous death of human splenic B cells by inducing the synthesis of bcl-2 protein [84].

IL-10 Receptor Signaling

The cDNA encoding a human IL-10R was originally isolated from a Burkitt lymphoma cell line and expressed in COS7 cells as a 90- to 110-kD protein [85]. The mouse IL-10R was similarly identified and expressed in a pro-B cell line (BaF3) that lacks IL-10 [86]. Based on sequence homology, the IL-10R was included with tissue factor, two subunits of the IFN- γ receptor (IFN- γ R1 and IFN- γ R2), and two subunits of the IFN- α receptor (IFN- α R1 and IFN- α R2) as a member of the type II cytokine receptor family. The original IL-10 receptor (IL-10R), now termed IL-10R1, primarily mediates high-affinity binding of IL-10. However, the observation that the single IL-10R chain did not reconstitute a functionally active receptor in fibroblasts led to




Fig. 1. IL-2R signaling depends on the JAK family of protein tyrosine kinases. The IL-10 homodimer binds to the IL-10R1 chain, leading to the formation of a complex with the IL-10R2 chain (CRF2-4). Jak1 binds to the IL-10R1 chain and Tyk2 interacts with the IL-10R2 chain. The Jak's phosphorylate specific tyrosine residues on the IL-10R1 chain, leading to STAT binding to the docking site on IL-10R1. STAT proteins then form dimers and translocate to the nucleus where they influence gene transcription.

the discovery of the second chain of the IL-10R CRF2-4. This chain, designated IL-10R2, joins the other members of the type II cytokine receptor family. It cooperates with the IL-10R1 chain for signaling [87, 88]. When the IL-10R1 chain interacts with IL-10 homodimer, it forms a complex with the IL-10R2 chain and initiates signal transduction [87, 89, 90].

The IL-10R utilizes the Janus family tyrosine kinase (JAK) signal transducers and activators of transcription (STAT) pathway [87, 88] (see fig. 1). Jak1 binds to the intracellular domain of the IL-10R1 chain [88]. Tyk2, another JAK family member, interacts with the IL-10R2 chain [88]. The JAKs phosphorylate specific tyrosine residues on the IL-10R1, which leads to the recruitment of STATs to their receptor docking site. IL-10 induces the activation of STAT-1, STAT-3 and STAT-5 [91]. STATs bind via their SH2 domains to the phosphorylated intracellular domain of the IL-2R1 chain. The STAT proteins are themselves activated by the JAKs. Tyrosine residues 427 and 477 are located within the intracellular domain of the mouse IL-10R1 and are required for IL-10 signaling [91, 92]. However, these two tyrosine residues are redundant in functional terms because mutant IL-10R1 chains expressing only one of these tyrosine residues behave similarly to the wild-type receptors [91, 92]. STATs can influence the regulation of many genes, including those for *c-fos*, *E-selectin*, *c-myc*, *ICAM-1* and *Fc γ RI* [93].

IL-10 signaling presumably requires and additional signal beyond the recruitment of STAT-3. Studies have shown that STAT-3 is obligatory but not sufficient for IL-10 to inhibit LPS-induced TNF- α production [92]. Moreover, O'Farrell et al. [94] have shown that IL-10 inhibits TNF- α production in a Stat-3-independent manner. The molecular chain of events leading to other regulatory signals is still unclear. Riley et al. [92] have shown that IL-10 inhibition of LPS-induced TNF- α production requires additional serine residues in the carboxyl terminus of the IL-10R1 chain, suggesting that another protein may bind to the IL-10R1 chain and mediate IL-10-induced anti-inflammatory effects.

IL-10 influences several intracellular signaling pathways. IL-10 has been reported to reduce LPS-induced activation of p56^{lck} and Ras [95]. Ras, a small G protein, activates Raf-1, which binds to MEK1 and activates the mitogen-activated protein kinase (MAPK) cascade. MAPK pathways include the extracellular signal-related kinase (ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38^{mapk} [93]. Some evidence has suggested that IL-10 does not effect LPS-induced activation of the MAPK kinases in human monocytes [96]. However, experiments in human dendritic cells show that TNF- α -induced phosphorylation of the MAPK cascade is significantly reduced by IL-10 [97]. Thus, in these experiments, IL-10 appears to block protein tyrosine kinase-mediated activation of ERK2, SAPK/JNK and p38^{mapk}. CD40 ligation by CD40 ligand (CD154) on T cells activates monocyte/macrophages to produce proinflammatory cytokines, which is similarly dependent on the generation of protein tyrosine kinase activity [98]. Suttles et al. [98] have shown using blood monocytes that CD40 signaling results in the phosphorylation of ERK1/2, but not SAPK/JNK or p38^{mapk}, and that preincubation with IL-10 reduces ERK1/2 kinase activity. Engagement of the IL-10R has also been shown to activate phosphatidylinositol 3-kinase and p70 S6 kinase, which stimulates monocyte proliferation without suppressing LPS-induced production of TNF- α or soluble TNF receptor [99]. Distinct signaling pathways may mediate the anti-inflammatory and proliferative effects of IL-10.

Animal Models

IL-10 antagonizes Th1 effector functions in vitro. The paradigm of a Th1-dependent immune reaction in vivo is delayed-type hypersensitivity (DTH). After recovery from *Leishmania major* infection, mice mount a highly polarized Th1 response after rechallenge with *L. major* antigen by injection of organisms into the footpads. Footpad swelling at 48 h after DTH induction is decreased by IL-10 treatment [100]. Neutralizing antibodies to IFN- γ fail to inhibit the

murine DTH response to *L. major* antigen, suggesting other cytokines mediate this response [100]. The DTH reaction induced by the injection of Th1 clones into mouse footpads is also inhibited by IL-10 treatment [101].

Susceptibility to certain protozoan, helminthic, and fungal infections is determined by innate immunity and the development of a strong Th1 response. Endogenous IL-10 may promote the survival of certain infectious agents by decreasing the induction of NO and microbicidal activity by macrophages and Th1-dependent synthesis of IFN- γ [102]. Treatment with anti-IL-10 antibody protects genetically susceptible DBA/2 mice from fatal *Candida albicans* infection, increases the frequency of IFN- γ -secreting splenic CD4⁺ T cells, and enhances macrophage capacity to produce NO [103]. In mice, high IL-10 doses exacerbate *C. albicans* [104] and *Listeria monocytogenes* [105] infection. In contrast, IL-10 may not be a factor in the outcome of murine leishmaniasis [106].

The control of infection involves a regulatory loop between IL-10 and IL-12. IL-10 treatment inhibits IL-12 production in IL-10-deficient mice infected with *Toxoplasma gondii* and protects against lethality in these animals from the overproduction of IL-12, TNF- α and IFN- γ [107]. In murine candidiasis, IL-12 induces IL-10 production by T cells and neutrophils [103, 108]. IL-12 genetically deficient mice infected with *C. albicans* show defective CD4⁺ Th1 cellular responses and attenuated macrophage production of IL-10 [109]. In these mice, short-term, low-dose IL-10 treatment expands the protective CD4⁺ T cell repertoire [109]. IL-10 may afford this protection by inhibiting CD8 α and CD86 expression on APCs, preventing the expansion of IL-4-producing CD4⁺ T cells, and skewing the immune responses to a Th1 phenotype [109]. Paradoxically, high IL-10 doses can exacerbate *C. albicans* infection in mice.

The importance of IL-10 in immune function has been investigated in IL-10 transgenic mice. In some transgenic mice, the IL-10 gene is driven by a T cell-specific promoter that regulates T cell-specific expression of IL-10 from the earliest stages of T cell stimulation. T cell-dependent oversecretion of IL-10 in this case inhibits IFN- γ production without stimulating IL-4 synthesis or antibody class switching [110]. IL-10 transgenic T cells fail in some instances to mediate Th1-dependent pathologic responses. Transfer of CD4⁺ CD45Rb^{hi} splenic T cells from normal mice to SCID or RAG-2^{-/-} immune-deficient recipients produces a Th1-mediated inflammatory bowel disease. However, this experimental disease is not transferred by CD4⁺ CD45Rb^{hi} T cells from the IL-10 transgenic mice [110]. The transgenic mice also develop larger tumors after injection of tumor cells than their nontransgenic littermates [110]. Not all Th-1 immune responses are defective in the IL-10 transgenics. These mice still develop a protective Th1 response

to *L. major* infection [110]. However, in another transgenic model where the T cells are engineered to overproduce IL-10, the mice show impaired control of mycobacterial infection [111].

IL-10 has also been overproduced in APCs which express a human IL-10 cDNA under the control of a mouse class II MHC E α promoter. Splenic macrophages from the APC IL-10 transgenics and their wild-type littermates do not differ in the expression of MHC molecules, ICAM-1 and CD86 molecules [112]. These IL-10 transgenics are characterized by certain defects in Th1- and Th2-type responses and show increased susceptibility to infection with *L. monocytogenes* and *L. major* [112]. Leishmaniasis infection progresses in these IL-10 transgenic mice despite protective Th1-like response to *L. major*, implying that IL-10 primarily acts to inhibit macrophage microbicidal effector functions. Treatment with a neutralizing anti-IL-10 antibody reverses the impaired host responses in these transgenic mice [112].

IL-10 is an important mediator in shock. Staphylococcal enterotoxin B, a superantigen, triggers IL-2 and TNF- α release into the circulation of mice, leading to shock. Staphylococcal enterotoxin B also promotes release of IL-10, which limits the deleterious effects of shock in this mouse model [113]. In LPS-challenged mice, pretreatment with IL-10 markedly reduces the amount of TNF- α released into the circulation and completely prevents mortality from shock [114]. However, exogenous IL-10 fails to decrease mortality in the more clinically relevant cecal ligation and puncture model of sepsis [115].

The biological effects of IL-10 have been investigated in experimental animal models of autoimmunity. Immunization with myelin antigens induces experimental allergic encephalomyelitis (EAE), a Th1-mediated disease characterized by weight loss, weakness of the tail and hind limbs, and ascending paralysis. Clinical recovery from EAE occurs with increased CNS expression of IL-10 [116]. Systemic administration of IL-10 during the initiation phase of EAE markedly suppresses the clinical manifestations of disease [117]. Mice expressing the human IL-10 transgene under the control of the MHC class II promoter are relatively resistant to EAE induction [118]. This inhibitory effect is probably related to the inability of the myelin-reactive Th1 cells to support effector cell function [118].

Systemic therapy with human IL-10 prevents the onset of diabetes in nonobese diabetic (NOD) mice [119]. IL-10-treated NOD mice show less insulinitis than untreated mice and their β cells secrete normal insulin levels [119]. A contrasting IL-10 effect on diabetes has been observed in transgenic mice engineered to express IL-10 in pancreatic β cells. In this case, local IL-10 production accelerates the onset of diabetes in the NOD mouse and increases its prevalence [120]. Transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) antigen in the pancreas develop diabetes after LCMV infection

[121]. IL-10 and LCMV double transgenic mice develop diabetes earlier than LCMV single transgenics. Thus, complex interactions, both systemic and local, determine the ultimate outcome of IL-10 treatment in the NOD mouse.

IL-10-deficient mice develop chronic colitis mediated by IFN- γ -secreting CD4 + T cells [122]. Only proximal bowel inflammation develops in transgenic mice kept under pathogen-free conditions, suggesting that the full-blown disease depends on antigen-specific stimulation by bacteria [122]. Treatment of IL-10-deficient mice with anti-IL-12 antibody prevents colitis in both young and adult mice, while anti-IFN- γ antibody treatment has only a minimal effect on established disease in the adult mice [123]. IL-12 presumably sustains the Th1 response during the chronic phase of this illness [123].

Transgenic mice expressing IL-10 under the control of a human salivary gland amylase promoter develop an exocrinopathy resembling Sjögren's syndrome [124]. The lacrimal and salivary glands in these mice are infiltrated with CD4 + T cells [124]. The glandular cells express high levels of Fas and are undergoing a high rate of apoptosis [124]. The infiltrating CD4 + T cells are polyclonal and express Fas ligand (FasL) [124], suggesting that glandular tissue destruction may result from nonspecific Fas/FasL interactions. IL-10 apparently can function either as an immunosuppressive or immunostimulatory cytokine depending on the model.

Evidence from animal models shows that IL-10 plays an important role in arthritis. Similar to RA in humans, type II collagen arthritis (CIA) in the mouse is characterized by synovial proliferation, the accumulation of leukocytes in the synovial tissue, and destruction of articular cartilage and subchondral bone. The development of arthritis is accompanied by expression of IL-10 in synovial macrophage-like and fibroblast-like cells as well as chondrocytes [125]. Mice treated with a neutralizing anti-IL-10 antibody show an acceleration of arthritis [125]. On the other hand, IL-10 treatment suppresses both early and established CIA [126, 127]. IL-10 administration reduces histologic signs of inflammation, TNF- α and IL-1 mRNA levels in synovial tissue, and cartilage and bone destruction [126, 127]. High doses of IL-12 boost IL-10 production in murine CIA and attenuate joint inflammation [128], providing further evidence that IL-10 is important in the pathogenesis of CIA. However, streptococcal cell wall-induced arthritis develops independent of IL-10 production despite the participation of T cells and macrophages [129].

Gene delivery of IL-10 has been investigated as a possible therapeutic strategy for arthritis. The overexpression of IL-10 in close proximity to a joint facilitates the maintenance of inhibitory concentrations at the desired site with potentially less systemic exposure. vIL-10 lacks immunostimulatory activity and thus may have therapeutic advantages over human or mouse IL-10. A nonreplicative adenovirus vector has been engineered to express vIL-10

(Adv-vIL-10) under the control of a specific promoter. Intravenous administration of Adv-vIL-10 delays the onset of murine CIA and reduces its severity [130, 131] in association with decreased splenic T cell responses to type II collagen [130]. Synovial tissue from successfully treated mice shows diminished inflammation [131] and lower levels of IL-2 and IL-1 mRNAs compared to control mice [130]. While gene delivery of vIL-10 suppresses the initiation of CIA, this approach fails to control established disease [130]. Moreover, other investigators find that intravenous Adv-vIL-10 injections have no effect on CIA [132]. In CIA, administration of Adv-vIL-10 by the intra-articular route exacerbates inflammation in the injected joint, but suppresses arthritis in the noninjected joints [130]. Periarthritic Adv-vIL-10 injection protects the joint from CIA in the proximity of the injection as well as reduces inflammation in the noninjected joints [132].

Gene therapy has also been examined in SCID mice engrafted subcutaneously with cartilage and synovial fibroblasts which have been transduced with a retroviral vector expressing the murine IL-10 or vIL-10 gene [133]. Both forms of IL-10 inhibit fibroblast invasion of cartilage, but have no effect on perichondrocytic cartilage degradation [133]. This inhibitory effect of IL-10 on fibroblast invasiveness has also been observed in a SCID mouse engrafted with human rheumatoid synovium and homologous cartilage [134]. Systemic vIL-10 delivery abrogated cartilage invasion by synovial tissue, but did not diminish the T cell infiltrate or decrease the IL-1, IL-6, TNF- α or IL-8 mRNA levels in synovial tissue [134].

IL-10 in RA

IL-10 is synthesized by macrophages and T cells in rheumatoid synovial tissue where it acts in concert with other factors to regulate the inflammatory response [5]. The immunoregulatory role of IL-10 has been investigated in synovial tissue cultures which spontaneously produce TNF- α , IL-1, IL-6 GM-CSF and IL-8 as well as IL-10 [5, 135]. These cell preparations are a heterogeneous population of synovial cells and immune cells. The addition of TNF- α and IL-1 stimulates IL-10 production in culture [5]. Synovial cell cultures incubated with anti-IL-10 antibody show higher levels of TNF- α and IL-1, indicating that endogenous sources of IL-10 are suppressing the production of these proinflammatory cytokines [5]. However, IL-10 blockade has little or no effect on IL-6 or IL-8 production [5]. On the other hand, exogenous IL-10 markedly reduces TNF- α and IL-1 levels in synovial cell cultures without significantly altering IL-6, IL-8 [5] or IL-1ra levels [135]. In other experiments, exogenous IL-10 has shown modest inhibi-

tory effects on IL-6 [135] and IL-8 production [136]. These results provide a rationale for using systemic IL-10 therapy as a means to reduce joint inflammation.

The effects of IL-10 may depend on contact with other cell types and mediators in the synovial microenvironment. This fact must be kept in mind when interpreting experiments using partially purified synovial cells. The addition of IL-10 to cultures of synovial fibroblasts does not affect IL-6 and GM-CSF production [137]. In contrast, similar experiments using a macrophage-like, CD14-enriched population of synovial cells find that IL-10 inhibits IL-6 production in culture [137]. IL-10 has been shown to inhibit synovial cell production of IL-1, IL-6, IL-8, G-CSF and GM-CSF production and IFN- γ -induced expression of HLA-DR, ICAM-1 and VCAM-1 in synovial cell cultures containing about 10% CD14+ macrophage-like cells [138]. Most of these observed IL-10 effects are probably dependent on macrophage-like synovial cells.

IL-10 and to a lesser extent IL-2 has the ability to stimulate antibody production in cocultures of synovioocytes with purified human tonsillar B cells [139]. Moreover, synovial fluid B cells produce increased amounts of IgM rheumatoid factor when they are cocultured with synovioocytes *in vitro* [140]. IL-10 also stimulates IgM rheumatoid factor production in this culture system [140]. These results suggest that upregulated expression of IL-10 may explain in part the accumulation of IgM rheumatoid factor-secreting B cells in the synovial microenvironment.

Synovial T cells represent an important source of IL-10. T cell clones isolated from the rheumatoid joint are predominantly Th1-like [141]. Most of the stimulated CD4+ T cell clones produce IFN- γ and IL-10. In agreement with these data, immunochemical analysis of synovial tissue shows 0.6% IFN- γ - and 1.5% IL-10-positive CD4+ T cells [141]. Stimulation of synovial CD4+ T cells with phorbol myristate acetate plus calcium ionophore also shows that most of the IL-10-secreting CD4+ T cells produce IFN- γ [142].

IL-10 mRNA and protein are detectable in synovial fluid from patients with RA [143, 144]. The main source of IL-10 in synovial fluid is the mononuclear cell, which spontaneously produces this cytokine in culture [144, 145]. In mononuclear cell cultures, exogenous IL-10 suppresses the production of TNF- α , IL-1 and GM-CSF, reduces the expression of HLA-DR molecules, enhances the expression of CD16 and CD64, and decreases spontaneous cell proliferation [144, 145]. Synovial fluid mononuclear cells stimulated with IL-10 in culture show increased expression of surface and soluble p75 receptor in culture [146].

IL-10 directly stimulates normal cartilage to synthesize proteoglycans [145]. Conditional media from antigen-stimulated synovial fluid mononu-

clear cells inhibit proteoglycan synthesis by cultured cartilage explants [145]. The cartilage degradation is largely dependent on the presence of IL-1 and TNF- α . IL-10 treatment of synovial fluid mononuclear cells reverses the inhibition of proteoglycan synthesis induced by the conditioned media [145].

Elevated IL-10 serum levels have been reported in patients with RA [143]. Peripheral blood mononuclear cells spontaneously produce IL-10 in vitro [147], and probably represent the main source of circulating IL-10. Although serum levels of IL-10 do not correlate with clinical measures of disease activity in RA, they do significantly correlate with serum rheumatoid factor titers and the amount of spontaneous IgM production in vitro [143]. IgM production in peripheral blood is dependent on endogenous IL-10 [148]. Blood monocytes incubated in culture with IL-10 show decreased production of TNF- α , IL-1 [145], and IL-6 [135] and increased expression of surface p55 and p75 TNF receptor and soluble p75 TNF receptor [146]. Both endogenous and exogenous TNF- α have been shown to mediate IL-10 release in vivo [149].

Clinical Studies of IL-10

The immunomodulatory effects and safety of systemic IL-10 administration has been studied in 17 healthy subjects randomized to receive a single intravenous bolus injection of 1, 10 or 25 μ g/kg recombinant human IL-10 or placebo [150]. IL-10 administration was associated with a transient neutrophilia, monocytosis, and lymphopenia, and a significant reduction in both the CD4 and CD8 T cell subsets [150]. The two highest doses of IL-10 produced up to a 50% decrease in mitogen-induced proliferation of peripheral blood mononuclear cells [150]. IL-10 also inhibited TNF- α and IL-1 production by whole blood stimulated ex vivo with endotoxin, but had no effect on soluble p55 TNF receptors or IL-1ra [150]. There were no significant adverse effects in this study.

A phase I dose-escalating, double-blind, placebo-controlled trial has been conducted in 72 patients with active RA [151]. In this trial, subjects were randomly allocated to receive daily subcutaneous injections for 4 weeks of either 0.5, 1.0, 5, 10 or 20 μ g/kg of recombinant human IL-10 or placebo. The recombinant IL-10 injections were well tolerated during the study. There was a reduction in platelet counts in subjects treated with the highest doses of IL-10, including 4 subjects receiving the 20 μ g/kg dose who had a platelet count decrease below 100,000/mm³. A trend towards clinical improvement was observed in the group receiving 5 μ g/kg of recombinant IL-10. The highest

dose groups had a significant increase in soluble p55 TNF and p75 receptor and IL-1ra levels.

Further trials have been performed in patients with RA using IL-10 as monotherapy or combined with methotrexate. A preliminary analysis has been completed for a phase II trial of IL-10 in patients with active RA receiving methotrexate therapy. The results suggest that subcutaneous injections of IL-10 as well tolerated and produce a favorable clinical response. A larger phase II/III trial of recombinant IL-10 therapy in patients with active RA is now in progress.

Conclusion

A growing understanding of the pathogenesis of joint inflammation has enabled rational targeting of specific pathways to achieve therapeutic goals. IL-10 interfaces with the cytokine cascade at several key points to maintain control over the inflammatory response, making it an attractive anti-inflammatory agent. Studies in animal models confirm the anti-inflammatory properties of IL-10 and reveal its complex interplay with other cytokines in the regulation of immune function and host defense. Clinical trials will ultimately provide the answer of whether the results in animal models can be extrapolated to a complex human disease such as RA.

References

- 1 Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell IV: TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. *J Exp Med* 1989;170:2081-2095.
- 2 Moore KW, O'Garra A, de Waal Malefyt R, Vieira F, Mosmann TR: Interleukin-10. *Annu Rev Immunol* 1993;11:165-190.
- 3 Mosmann TR: Properties and functions of interleukin-10. *Adv Immunol* 1994;56:1-26.
- 4 Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. *Arthritis Rheum* 1993;38:151-160.
- 5 Katikis PD, Chu C-Q, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. *J Exp Med* 1994;179:1517-1527.
- 6 Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H, Woody JN: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. *Lancet* 1994;344:1105-1110.
- 7 Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schelle TF, Feldmann M: Therapeutic efficacy of multiple infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1998;41:1552-1563.
- 8 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Wexner AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blusch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med* 1997;337:141-147.

- 9 Weinblatt ME, Kremer JM, Bankhurst AD, Bugatti KJ, Fleischmann RM, Fox RL, Jackson CG, Lange M, Buge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253-259.
- 10 Morfand LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bugatti KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Atfield DG, Garrison L, Buge DJ, Bloch CM, Lange ML, McDonnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. *Ann Intern Med* 1999;130:478-486.
- 11 Bresnahan B, Alvaro-Gracia JM, Cobley M, Doherty M, Donlin Z, Emery P, Nuki G, Pavelka K, Raa R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Muskie P: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998;41:2196-2204.
- 12 Moore KW, Vieira P, Fiorentino DF, Trounstein ML, Khan TA, Mosmann TR: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. *Science* 1990;248:1230-1234.
- 13 Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kaselien R, Fiorentino DF, de Vries JE: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BDRF1. *Proc Natl Acad Sci USA* 1991;88:1172-1176.
- 14 de Waal-Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. *J Exp Med* 1991;174:1209-1220.
- 15 Wanduwanan C, Strober W: Predominant role of tumor necrosis factor- α in human monocyte IL-10 synthesis. *J Immunol* 1993;151:6853-6861.
- 16 Parry SL, Sebbag M, Feldmann M, Brennan FM: Contact with T cells modulates monocyte IL-10 production. Role of T cell membrane TNF- α . *J Immunol* 1997;158:3673-3681.
- 17 Meada H, Kuwahara H, Ichimura Y, Ohnishi M, Kurakawa S, Shirahata A: TGF- β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. *J Immunol* 1995;155:4926-4932.
- 18 Anan M, Treitter T, Eisenbeis L, Bug G, Decker T, Aulitzky WE, Tilg H, Huber C, Peschel C: Interferon- α stimulates production of IL-10 in activated CD4⁺ T cells and monocytes. *Blood* 1996;87:4731-4736.
- 19 Porriani AM, Gambi D, Reder AT: Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. *J Neuroimmunol* 1993;50:27-34.
- 20 Dugas N, Wouda J, Bacher P, Arock M, Debet P, Tardieu M, Mossalayi DM, Delmas JF, Kolb JP, Dugas B: Triggering of CD23b antigen by anti-CD23 monoclonal antibodies induces interleukin-10 production by human macrophages. *Eur J Immunol* 1996;26:1394-1398.
- 21 Sauterova ES, Noel GJ, Salgame P, Moser DM: Reversal of proinflammatory responses by ligating the macrophage Fc γ receptor type 1. *J Exp Med* 1998;188:217-222.
- 22 Elenkov IJ, Webster E, Papantolou DA, Fleisher TA, Chrousos GP, Wilder RL: Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. *J Immunol* 1998;161:2586-2593.
- 23 Chomman P, Risoan M, Bancheau J, Mosser P: Interferon γ inhibits interleukin 10 production by monocytes. *J Exp Med* 1993;177:523-527.
- 24 Bonder CS, Finlay-Jones JJ, Hart PH: Interleukin-4 regulation of human monocyte and macrophage interleukin-10 and interleukin-12 production. Role of a functional interleukin-2 γ -chain. *Immunology* 1999;96:529-536.
- 25 Mosser P, van den Berg W: Th1/Th2 cytokine balance in arthritis. *Arthritis Rheum* 1997;40:2105-2115.
- 26 Assmann M, Lohning M, Scheffold A, Richter A, Miltenyi S, Schmitz J, Radbruch A: Commitment of individual Th1-like lymphocytes to expression of IFN- γ versus IL-4 and IL-10: Selective induction of IL-10 by sequential stimulation of naive Th cells with IL-12 and IL-4. *J Immunol* 1998;161:2823-2832.

- 27 Kuratsis PD, Cohen SBA, Londei M, Feldmann M: Are CD4⁺ T_H cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN- γ or IL-2 determines their function. *Int Immunol* 1995;7:1287-1294.
- 28 Naora H, Altin JG, Young IG: TCR-dependent and -independent signaling mechanisms differentially regulate lymphokine gene expression in the murine T helper clone D10.G4.1. *J Immunol* 1994;152:5691-5702.
- 29 Schmidt-Weber CB, Alexander SI, Hemault LE, James L, Lichtman AH: IL-4 enhances IL-10 gene expression in murine Th2 cells in the absence of TCR engagement. *J Immunol* 1999;162:238-244.
- 30 Levite M: Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. *Proc Natl Acad Sci USA* 1998;95:12544-12549.
- 31 Melnrota PJ, Donnelly RP, Wong S, Kanevane H, Greenawald A, Mostowski HS, Furukawa K, Siegel JP, Bloom ET: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. *J Immunol* 1998;160:2637-2644.
- 32 Zan H, Cerutti A, Dramitinos P, Schaffer A, Casali P: CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of TGF- β : Evidence for TGF- β but not IL-10-dependent direct Sp-5 α and sequential Sp-5 α , Sp-5 β DNA recombination. *J Immunol* 1998;161:5217-5225.
- 33 Burdick N, Petrone C, Bancheau J, Rouselet F: Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. *J Exp Med* 1993;177:295-304.
- 34 Benjamin D, Knobloch TJ, Dayton MA: Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. *Blood* 1992;80:1289-1298.
- 35 Lin TJ, Betts AD: Differential regulation of mast cell function by IL-10 and stem cell factor. *J Immunol* 1997;159:4015-4023.
- 36 Becherel PA, LeGoff L, Frances C, Chosidow O, Guillemin JJ, Debre P, Mossalayi MD, Arock M: Induction of IL-10 synthesis by human keratinocytes through CD23 ligand: A cyclic adenosine 3',5'-monophosphate-dependent mechanism. *J Immunol* 1997;159:5761-5765.
- 37 Ekdale J, Gallagher G, Verweij CL, Keijzers V, Westendorp RGJ, Huizinga TWJ: Interleukin 10 secretion in relation to human IL-10 locus haplotypes. *Proc Natl Acad Sci USA* 1998;95:9465-9470.
- 38 Brown CY, Laguarda CA, Vadas MA, Goodall GJ: Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10. *J Biol Chem* 1996;271:20108-20112.
- 39 Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomma DI, Vandenbrouke JP: Genetic influence on cytokine production and fatal meningococcal disease. *Lancet* 1997;349:170-173.
- 40 Marchant A, Deviller J, Byl B, De Groote D, Vincent J, Goldmann M: Interleukin-10 production during septicemia. *Lancet* 1994;343:707-708.
- 41 Kube D, Platzner C, von Knethen A, Straub H, Bohlen H, Halfer M, Tesch H: Isolation of the human interleukin 10 promoter: Characterization of the promoter activity in Burkitt's lymphoma cell lines. *Cytokine* 1995;7:1-7.
- 42 Ekdale J, Kube D, Tesch H, Gallagher G: Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. *Immunogenetics* 1997;46:120-128.
- 43 Ekdale J, Gallagher G: A polymorphic dinucleotide repeat in the human IL-10 promoter. *Immunogenetics* 1995;42:444-445.
- 44 Ekdale J, Kube D, Gallagher G: A second polymorphic dinucleotide repeat in the 5' flanking region of the human IL10 gene. *Immunogenetics* 1996;45:82-83.
- 45 Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnett PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. *Eur J Immunogenet* 1997;24:1-8.
- 46 Crawley E, Kay R, Sinbourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes in the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. *Arthritis Rheum* 1999;42:1101-1108.
- 47 Mori N, Prager D: Activation of the interleukin-10 gene in the human T lymphoma line HuT 78: Identification and characterization of Nkx2 binding sites in the regulatory region of the interleukin-10 gene. *Eur J Haematol* 1997;59:162-170.

- 48 Cunniff A, Naveau F, Loubet-Lescoult P, Nourhashemi F, Enault G, Abbel M, Constantin A, Laroche M, Mazères B. Interleukin-1 β , interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms. Relationship to occurrence and severity in rheumatoid arthritis. *Arthritis Rheum* 1999;42:1093-1100.
- 49 Cookley G, Mok CC, Huijter AH, Ollier WER, Turner D, Simoni PJ, Hutchinson IV, Panayi GS, Lanchbury JS. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. *Br J Rheumatol* 1998;37:988-991.
- 50 Eskdale J, McNicholl J, Wordsworth P, Jones B, Huizinga T, Field M, Galloway G. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. *Lancet* 1998;352:1282-1283.
- 51 de Waal Malefyt R, Haanen J, Spit H, Romancio M, te Velde A, Figdor C, Johnson K, Kastlein R, Yssel H, de Vries JE. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. *J Exp Med* 1991;174:915-924.
- 52 Bogdan C, Paik J, Vodovotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. *J Biol Chem* 1992;267:23301-23308.
- 53 Wang P, Wu P, Siegel M, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood. *J Immunol* 1994;153:811-816.
- 54 Del Prete G, de Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. *J Immunol* 1993;150:353-360.
- 55 Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. *J Immunol* 1991;146:3444-3451.
- 56 Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. Interleukin-10 down-regulates MHC class II gp peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. *Immunol* 1997;7:861-871.
- 57 Williams F, Marchant A, Deville J, Girard C, Delvaux A, Velu T, de Boer M, Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. *Eur J Immunol* 1994;24:1007-1009.
- 58 Aste-Amezaga M, Ma X, Sarton A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. *J Immunol* 1998;160:5936-5944.
- 59 Horton MR, Burdick MD, Stricker RM, Bao C, Noble PW. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN- γ in mouse macrophages. *J Immunol* 1998;160:3023-3030.
- 60 Sherry B, Espinoza M, Manogue KR, Cerami A. Induction of the chemokine β peptides, MIP-1 α and MIP-1 β , by lipopolysaccharide is differentially regulated by immunomodulatory cytokines IFN- γ , IL-10, IL-4, and TGF- β . *Mol Med* 1998;4:648-657.
- 61 Metz PM, DeWitt DL, Steller-Stevens WG, Wahl LM. Interleukin-10 suppression of monocyte prostaglandin H synthase-2. *J Biol Chem* 1994;269:21322-21329.
- 62 Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. *J Exp Med* 1991;174:1549-1555.
- 63 Cerri E, Romani L, Mencacci A, Spaccapelo R, Schiaffella E, Puccetti P, Bissoni F. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of *Candida albicans*. *Eur J Immunol* 1993;23:1034-1038.
- 64 St. Clair EW, Wilkinson WE, Lang T, Sanders L, Mialoukis MA, Gilkeson GS, Pleschky DS, Granger DL, Weinberg JB. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. *J Exp Med* 1996;184:1173-1178.
- 65 Joyce DA, Gibbons DP, Green P, Sier JH, Feldmann M, Brennan FM. Two inhibitors of proinflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. *Eur J Immunol* 1994;24:2699-2705.
- 66 Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 β production in human monocytes and neutrophils. *Lymphokine Cytokine Res* 1994;13:47-54.
- 67 Bovolenta C, Gasperini S, McDonald PR, Cassatella MA. High affinity receptor IgG (Fc γ R/CD64) gene and STAT protein binding to the IFN- γ response region (GRR) are regulated differentially in human neutrophils and monocytes by IL-10. *J Immunol* 1998;160:911-919.
- 68 de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. *J Immunol* 1993;150:4734-4765.
- 69 Taga K, Tosiato G. IL-10 inhibits human T cell proliferation and IL-2 production. *J Immunol* 1992;148:1143-1148.
- 70 Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* 1997;389:737-742.
- 71 Blazar BR, Taylor PA, Smith S, Valera DA. Interleukin-10 administration decreases survival in murine recipients of minor histocompatibility complex disparate donor bone marrow grafts. *Blood* 1995;85:862-851.
- 72 Matsuda M, Salazar F, Peterson M, Masucci G, Hanson J, Piss P, Zhang Q, Masucci MG, Kessler J. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. *J Exp Med* 1994;180:2371-2376.
- 73 Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. *J Immunol* 1998;160:3188-3193.
- 74 Taga K, Chretien J, Chenery B, Diaz L, Brown M, Tosiato G. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. *J Clin Invest* 1994;94:251-260.
- 75 Taga K, Chenery B, Tosiato G. IL-10 inhibits apoptotic cell death in human f cells starved of IL-2. *Int Immunol* 1993;5:1599-1608.
- 76 Wang P, Anthe JC, Siegel M, Egan RW, Billah MM. Interleukin-10 inhibits interleukin-8 production in human neutrophils. *Blood* 1994;83:2678-2683.
- 77 Thivierge M, Parent J, Stankeva J, Kola-Piszczynski M. Modulation of formyl peptide receptor expression by IL-10 in human monocytes and neutrophils. *J Immunol* 1999;162:3590-3595.
- 78 Takamaki S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M. Interleukin-10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. *J Exp Med* 1994;180:711-715.
- 79 Kucharzik T, Luger N, Puetz HG, Domschke W, Stoll R. IL-4, IL-10 and IL-13 downregulate monocyte-chemottracting protein-1 (MCP-1) production in activated epithelial cells. *Clin Exp Immunol* 1998;111:155-157.
- 80 Roussel F, Garcia E, Defrance T, Peronne C, Vezio N, Hsu DH, Kastlein R, Moore KW, Bancheau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. *Proc Natl Acad Sci USA* 1992;89:1890-1893.
- 81 Thompson-Stolpe L, Obar V, Bond MW, Mosmann TR, Moore KW, Remick DM. Interleukin 10: A novel immunostimulatory factor for mast cells and their progenitors. *J Exp Med* 1991;173:507-510.
- 82 Meckell JA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth factor for mature and immature T cells. *J Immunol* 1990;145:4167-4173.
- 83 Jeanin P, Lecouet S, Delneste Y, Gaudin J, Bonnefoy J. IgE versus IgG4 production can be differentially regulated by IL-10. *J Immunol* 1998;160:3555-3561.
- 84 Levy Y, Brovet J. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. *J Clin Invest* 1994;93:424-428.
- 85 Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. *J Immunol* 1994;152:1821-1829.
- 86 Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. *Proc Natl Acad Sci USA* 1993;90:11267-11271.
- 87 Konoike S, Krause CD, Izotova LS, Pollack BR, Wu W, Pestka S. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. *EMBO J* 1997;16:5894-5903.

- 88 Spencer SD, Di Marco F, Hooley J, Pitts-Meck S, Bauer M, Ryan AM, Sordal B, Gibbs VC, Aguet M. The opium receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. *J Exp Med* 1998;187:571-578.
- 89 Tan JC, Indelicato SR, Narula SK, Zawodny PJ, Chou CC. Characterization of interleukin-10 receptors on human and mouse cells. *J Biol Chem* 1993;268:21053-21059.
- 90 Tan JC, Braun S, Rong H, DiGiacomo R, Dolphin E, Balaban S, Narula SK, Zawodny PJ, Chou CC. Characterization of recombinant extracellular domain of human interleukin-10 receptor. *J Biol Chem* 1995;270:12906-12911.
- 91 Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. *J Biol Chem* 1996;271:27954-27961.
- 92 Riley JK, Takada K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. *J Biol Chem* 1999;274:16513-16521.
- 93 Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. *Arthritis Rheum* 1999;42:609-621.
- 94 O'Farrell A-M, Liu Y, Moore KW, Muir AL-F. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and -independent pathways. *EMBO J* 1998;17:1006-1018.
- 95 Geng Y, Guibins E, Altman A, Loiz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. *Proc Natl Acad Sci USA* 1994;91:8602-8606.
- 96 Frey AD, Pury SL, Williams LM, Feldmann M, Foxwell BMJ, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF- α . Role of the p38 and p3244 mitogen-activated protein kinases. *J Immunol* 1998;160:920-928.
- 97 Saito K, Nagayama H, Tadokoro K, Jui T, Takahashi TA. Extracellular signal-regulated kinase, stress-activated protein kinase/Jun N-terminal kinase, and p38 γ are involved in IL-10-mediated selective repression of TNF- α -induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. *J Immunol* 1999;162:3865-3872.
- 98 Suttles J, Milthorpe DM, Miller RW, Poe JC, Wahl LM, Stout RD. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (IL)-4 and IL-10 anti-inflammatory action. *J Biol Chem* 1999;274:5835-5842.
- 99 Crawley JB, Williams LM, Maeder T, Brennan FM, Foxwell BMJ. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the anti-inflammatory effects of the cytokine. *J Biol Chem* 1996;271:16357-16362.
- 100 Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. *Eur J Immunol* 1993;23:2223-2229.
- 101 Li L, Elliott JF, Mosmann TR. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. *J Immunol* 1994;153:3667-3678.
- 102 Gazzinelli RT, Oswald IP, James SL, Sier A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN- γ -activated macrophages. *J Immunol* 1992;148:1792-1796.
- 103 Roman L, Puccetti P, Menocci A, Cenci E, Spaccapelo R, Tonetti L, Grohmann U, Bistoni F. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with *Candida albicans*. *J Immunol* 1994;152:3514-3521.
- 104 Tonetti L, Spaccapelo R, Cenci E, Menocci A, Puccetti P, Coffman RL, Bistoni F, Roman L. Interleukin-4 and interleukin-10 exacerbate candidiasis in mice. *Eur J Immunol* 1995;25:1559-1565.
- 105 Kelly JP, Bancroft GF. Administration of interleukin-10 abolishes innate resistance to *Listeria monocytogenes*. *Eur J Immunol* 1996;26:356-364.
- 106 Henzel FP, Sadek MD, Mutha SS, Locksley RM. Production of interferon γ , interleukin 2, interleukin 4, and interleukin 10 by CD4⁺ lymphocytes in vivo during healing and progressive murine leishmaniasis. *Proc Natl Acad Sci USA* 1991;88:7011-7015.
- 107 Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sier A. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4⁺ T cells and accompanied by overproduction of IL-12, IFN- γ and TNF- α . *J Immunol* 1996;157:798-805.

- 108 Roman L, Menocci A, Cenci E, Spaccapelo R, Del Sero G, Nicoletti I, Trinchieri G, Bistoni F, Puccetti P. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. *J Immunol* 1997;158:5349-5356.
- 109 Menocci A, Cenci E, Del Sero G, Fe d'Ostiani C, Mosci P, Trinchieri G, Adorini L, Roman L. IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon *Candida albicans* infection. *J Immunol* 1998;161:6228-6237.
- 110 Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Armada R, Chetroure H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. *J Exp Med* 1997;185:2101-2110.
- 111 Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. *J Immunol* 1997;158:315-321.
- 112 Groux H, Coltey F, Rouleau M, Mauze S, Antonenko S, Hurst S, McNeil T, Bigler M, Roncarolo M, Coffman RL. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. *J Immunol* 1999;162:1723-1729.
- 113 Florquin S, Ammou Z, Abramowicz D, Goldman M. Systemic release and protective role of IL-10 in suppurative enterocolitis B-induced shock in mice. *J Immunol* 1994;153:2618-2623.
- 114 Gerard C, Brynys C, Marchant A, Abramowicz D, Vandebroucke P, Delvaux A, Fiers W, Goldman M, Veldu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. *J Exp Med* 1993;177:547-550.
- 115 Remick DG, Garg SL, Newcomb DE, Wolleberg G, Huie TK, Bolgos GL. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. *Crit Care Med* 1998;26:983-994.
- 116 Kennedy MK, Torrance DS, Pichu KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. *J Immunol* 1992;149:2406-2409.
- 117 Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. *Eur J Immunol* 1994;24:1434-1440.
- 118 Cui DJ, Groux H, Hinton DR, Stohman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. *J Exp Med* 1999;189:1005-1010.
- 119 Penhale KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. *Clin Immunol Immunopathol* 1994;71:169-175.
- 120 Wogenen L, Lee M, Sarvenik N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. *J Exp Med* 1994;179:1379-1384.
- 121 Lee M, Wogenen L, Shizuru J, Oldstone MBA, Sarvenik N. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. *J Clin Invest* 1994;93:1332-1338.
- 122 Kohn R, Lohrer J, Remick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic colitis. *Cell* 1993;75:263-274.
- 123 Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Remick DM. IL-12, but not IFN- γ , plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. *J Immunol* 1998;161:3143-3149.
- 124 Saito I, Hara K, Shimizu M, Inoue H, Sakurai H, Ishimaru N, Higashiyama H, Sunada T, Ishida H, Suda T, Noda T, Hayashi Y, Tsubota K. Fas ligand-mediated enterocolitis resembling Silegion's syndrome in mice transgenic for IL-10. *J Immunol* 1999;162:2488-2494.
- 125 Kassama T, Streeter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin-10 expression and dendritic regulation during the evolution of murine type II collagen-induced arthritis. *J Clin Invest* 1995;95:2868-2876.
- 126 Wainstein M, Kautsky PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. *Arthritis Rheum* 1996;39:495-503.
- 127 Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. *Arthritis Rheum* 1997;40:249-260.

- 128 Kasama T, Yamazaki J, Hanabuchi R, Miwa Y, Matsuo Y, Kobayashi K, Negishi M, Ito H, Adachi M: Biphasic regulation of the development of murine type II collagen-induced arthritis by interleukin-12. Possible involvement of endogenous interleukin-10 and tumor necrosis factor alpha. *Arthritis Rheum* 1999;42:100-109.
- 129 Schliemer RC, Schrier DJ, Flory CM, Lemaire KD, Tung D, Metz AL, Friedl HP, Conroy MC, Warren JS, Beck R, Ward PA: Streptococcal cell wall-induced arthritic requirements for IL-4, IL-10, IFN-gamma, and monocyte chemoattractant protein-1. *J Immunol* 1998;160:1466-1471.
- 130 Ma Y, Thomson S, Duvel LE, Boivin CP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R: Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. *J Immunol* 1998;161:1516-1524.
- 131 Appurilly F, Verwerde C, Jaquet C, Aurault C, Sany J, Jorgensen C: Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. *J Immunol* 1998;160:5213-5220.
- 132 Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovacs I, Gortoso JC, Robbins PD, Evans CH: Adenoviral transfer of the viral IL-10 gene periticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and un.injected paws. *J Immunol* 1999;162:3625-3632.
- 133 Muller-Ladner U, Evans CH, Franklin BN, Roberts CR, Gay RE, Robbins PD, Gay S: Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. *Arthritis Rheum* 1999;42:490-497.
- 134 Jorgensen C, Appurilly F, Canova F, Verwerde C, Aurault C, Jaquet C, Sany J: Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice. *Arthritis Rheum* 1999;42:678-685.
- 135 Chomarat P, Banchereau J, Miossec P: Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis. *Arthritis Rheum* 1995;38:1046-1054.
- 136 Sugiyama E, Kuroda A, Taki H, Ikenoto M, Hori T, Yamashita N, Maruyama M, Kobayashi M: Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. *J Rheumatol* 1995;22:2020-2026.
- 137 Dechantel J, Risseau M, Banchereau J, Miossec P: Interleukin 4, but not interleukin 10, regulates the production of inflammatory mediators by rheumatoid synovial cells. *Cytokine* 1995;7:176-183.
- 138 Kawakami A, Eguchi K, Matsuda N, Tsuboi M, Urayama S, Kawabe Y, Aoyagi T, Machi K, Nagai S: Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis. *Immunology* 1997;91:232-239.
- 139 Dechantel J, Merville P, Durand I, Banchereau J, Miossec P: The ability of synovial cells to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. *J Clin Invest* 1995;95:456-463.
- 140 Reparon-Schulz CC, van Esch WJE, van Kooten C, Lervath EWN, Bredveld FC, Verweij CL: Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. *Arthritis Rheum* 1998;41:2211-2220.
- 141 Cohen SBA, Katsis PD, Chu C, Thomsen H, Webb LM, Maini RN, Londe M, Feldman M: High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. *Arthritis Rheum* 1995;38:946-952.
- 142 Morita Y, Yamamura M, Kawashima M, Harada S, Tsuji K, Shibuya K, Maruyama K, Makino H: Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. *Arthritis Rheum* 1998;41:1669-1676.
- 143 Cui JJ, Splawski JB, Thomas R, McFarlin JE, Schulz-Koops H, Davis LS, Fujita K, Lipsky PE: Elevated interleukin-10 levels in patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:96-104.
- 144 Isomaki P, Laakkonen R, Saurio R, Toivanen P, Punnonen J: Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. *Arthritis Rheum* 1996;39:386-395.
- 145 van Rooij JAG, van Roy JAAM, Gmelig-Meyling FHJ, Latheer FPG, Blijnsma JWJ: Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. *Arthritis Rheum* 1996;39:829-835.
- 146 Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ: Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. *J Immunol* 1996;157:3672-3680.

- 147 Llorente L, Richard-Pain Y, Fior R, Alcocer-Varela J, Wajsbien J, Fourier BM, Gahmrad P, Emile D: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. *Arthritis Rheum* 1994;37:1647-1655.
- 148 Perez L, Orte J, Brieve JA: Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10. *Arthritis Rheum* 1995;38:1771-1776.
- 149 van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer JH: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. *J Exp Med* 1994;180:1985-1998.
- 150 Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. *J Immunol* 1995;154:5492-5499.
- 151 Maini RN, Paulus H, Bredveld FC, Moreland LW, St Clair EW, Russell AS, Charles P, Davies D, Grint P, Wherry JC, Feldmann M: rIL-10 in subject with active rheumatoid arthritis (RA): A phase I and cytokine response study. *Arthritis Rheum* 1997;40(suppl):S274.

E. William St. Clair, MD, Room 34229, Duke South Hospital,
Box 3874, Duke University Medical Center, Erwin Road, Durham, NC 27710 (USA)
Tel: +1 (919) 684 4499, Fax: +1 (919) 684 8358, E-Mail: stclai003@mc.duke.edu